PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has published a turnover of €1,749,000 for the second quarter of 2008, compared with €199,000 recorded for the same period in 2007. The company also presented the initial trends for Loramyc® sales in France and its plan for marketing in Europe.
